Fintel reports that on February 21, 2025, William Blair downgraded their outlook for Parsons (NYSE:PSN) from Outperform to Market Perform. Analyst Price Forecast Suggests 97.12% Upside As of February ...

TD Cowen downgraded Parsons (PSN) to Hold from Buy with a price target of $56, down from $105. The company’s “sharp 2025 rowth deceleration and ...

Earnings rose at Parsons in the fourth quarter and the full year of 2024, the company reported early Wednesday. Net earnings ...

Q4 2024 Earnings Call Transcript February 19, 2025 Parsons Corporation misses on earnings expectations. Reported EPS is $0.78 ...

In a report released today, Sangita Jain from KeyBanc maintained a Buy rating on Parsons (PSN – Research Report). The company’s shares closed ...

Innovative lipid nanoparticles enable mRNA delivery to the brain, offering new avenues for treating neurological disorders by crossing the blood-brain barrier.

Scientists at the Icahn School of Medicine at Mount Sinai have developed a lipid nanoparticle system capable of delivering ...